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Resumo 
Introdução: O diagnóstico de tumores ósseos e de tecidos moles é muitas vezes um processo complexo, 
em que a escolha do melhor método assume uma importância vital. Neste sentido, o interesse na 
citologia aspirativa por agulha fina tem vindo a aumentar, não tendo ainda atingido o valor da biopsia 
por trucut, que é considerado o método de eleição, em alternativa à biopsia cirúrgica. No entanto, em 
centros especializados, os resultados obtidos com esta técnica são muito positivos, e demonstram o seu 
elevado potencial. Para além destes factos, é de realçar a sua utilidade na implementação das primeiras 
atitudes terapêuticas, sobretudo quando são integrados os elementos clínicos e imagiológicos existentes, 
mesmo em casos em que não se obtém um diagnóstico histológico preciso. 
 
Objectivos: Avaliar a capacidade diagnóstica da biopsia por agulha fina e analisar em que medida este 
método possibilita o início do tratamento, esclarecendo o seu papel na abordagem das lesões músculo-
esqueléticas. 
 
Material e Métodos: Retrospectivamente, foram revistos os casos de doentes submetidos à realização 
de biopsia citológica por agulha fina e biopsia por trucut num mesmo procedimento, ao longo de dois 
anos (2011-2012), no Hospital Santo António - Centro Hospitalar do Porto. 
Assim, foram estudados 88 doentes. Destes, 63 foram submetidos a biopsia óssea e 25 a biopsia de 
tecidos moles, com localização variável. O controlo de imagem foi efectuado por tomografia (n=54), 
ultra-sonografia (n=18) e radioscopia (n=16). Foram avaliados o rendimento e a precisão diagnóstica 
global da biopsia por agulha fina, e ainda o rendimento e a precisão da técnica em subgrupos específicos. 
Posteriormente, sob supervisão de especialista na área, os diagnósticos foram validados quanto à sua 
utilidade terapêutica e ao potencial para iniciar tratamento. 
 
Resultados: Dos 88 doentes estudados, em 72 (81,8%) obteve-se um diagnóstico com a biopsia por 
agulha fina. Destes últimos, 63 (71,6%) tiveram um diagnóstico exacto, e nos restantes 9 (10,2%) só foi 
possível concluir se a lesão era maligna (n=2) ou benigna (n=7). Em 58 (65,9%) o diagnóstico foi 
concordante com biopsia por trucut, e em 5 (5,7%) o resultado obtido foi incorrecto. A biopsia por 
agulha fina foi inconclusiva em 16 (18,2%) casos. 
No estudo, o rendimento global da biopsia por agulha fina foi de 81,8%, a precisão global de 92%, e 
relativamente à possibilidade de início de tratamento, verificou-se que tal foi possível em 90,3% dos 
casos com diagnóstico. 
 
Discussão: Este estudo corrobora estudos e revisões prévias na medida em que valida a biopsia por 
agulha fina como método com alto rendimento e precisão diagnóstica nos tumores músculo-esqueléticos 
e nas lesões que habitualmente entram no seu diagnóstico diferencial.  
Para além destes factos, assume-se como procedimento de grande utilidade na abordagem inicial destas 
patologias, na medida em que permite o início do tratamento na grande maioria dos casos.  
 
 
 
Palavras-chave: lesões músculo-esqueléticas; biopsia por agulha fina; citologia aspirativa; biopsia por trucut; 
tumores ósseos; diagnóstico. 
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Abstract 
 
Introduction: The diagnosis of bone and soft tissue tumors is often a complex process, in which the 
choice of the best method is of vital importance. The interest in fine needle aspiration cytology has been 
increasing but it has not yet reached the value of trucut biopsy, which is considered the main alternative 
to surgery biopsy. However, in specialized centers, the results obtained with the former technique are 
encouraging, and demonstrate the high potential of this procedure. In addition, it is worth it to highlight 
the therapeutic utility of the fine needle biopsy, particularly when the clinical and imaging elements are 
integrated, even in cases where a histologic diagnosis is not achieved. 
 
Objectives: To evaluate the diagnostic capacity of fine-needle biopsy, and analyze to what extent this 
method enables the initiation of treatment, clarifying its role in addressing musculoskeletal tumors. 
 
Material and Methods: Retrospectively, we reviewed the cases of patients who underwent in the 
same procedure a cytological fine needle and a trucut biopsy, for a two years period (2011-2012), at 
Hospital Santo António – Centro Hospitalar do Porto. 
88 patients were studied. Of these, 63 underwent bone biopsies and 25 biopsy of soft tissue at variable 
locations. The imaging control of the biopsies was performed by CT scan (n = 54), ultrasonography (n = 
18) and radioscopy (n = 16). The yield and overall diagnostic accuracy of fine-needle biopsy were 
evaluated and also the yield and accuracy of this technique in specific subgroups. Later, under the 
supervision of a specialist in the area, the diagnoses were validated for their therapeutic utility and the 
potential to start treatment. 
 
Results: In 72 patients (81.8%) a diagnosis with fine-needle biopsy was obtained. Of these, 63 (71.6%) 
had an accurate diagnosis, and the remaining 9 (10.2%) the only possible conclusion regarded whether 
the lesion was malignant (n = 2) or benign (n = 7). In 58 (65.9%) the diagnosis was in agreement with 
trucut biopsy, and in 5 (5.7%) the result was incorrect. The fine needle biopsy was inconclusive in 16 
(18.2%) cases. 
The overall diagnostic yield of the fine needle biopsy was 81.8% and the overall accuracy of 92%. The 
technique permitted the initiation of treatment in 90.3% of diagnosed cases. 
 
Discussion: This study confirms previous studies and reviews as it validates the fine needle biopsy as a 
method with high yield and diagnostic accuracy in musculoskeletal tumors and lesions that usually enter 
the differential diagnosis. 
In addition to these facts, it is a useful procedure in approaching these pathologies, in that it allows the 
start of treatment in most cases. 
 
 
Key words: musculoskeletal lesions, Fine needle aspiration; cytology aspiration, trucut biopsy; bone tumors; 
diagnosis. 
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Introduction 
 
Malignant tumors of bone and soft tissues are rare neoplasms, and due to their low prevalence, it is 
difficult to study their morphology, and obtain their diagnosis, highlighting the importance of specialized 
centers in the study and follow-up of these patients. 1-3 
An incorrect diagnosis can adversely affect the prognosis and can make the difference between 
preserving or amputating a limb. 
After a proper clinical and imaging evaluation, the biopsy is the final step in obtaining a diagnosis in bone 
and soft tissue tumors. Through the analysis of the collected material, information for making important 
decisions can be obtained, such as the nature of the lesion (benign / malignant), the degree of 
malignancy and the histological and cytological analysis. 
Currently, the two main techniques used for the diagnosis of these pathologies are trucut biopsy (Core 
Needle Biopsy - CNB) and surgical biopsy (incisional / excisional). However, fine needle biopsy (Fine 
Needle Aspiration - FNA) has been gaining a lot of support. This procedure consists in obtaining tissue 
using a needle of 20- gauge or thinner. Initially, only superficial tumors could be addressed but with the 
use of imaging techniques, it has become possible to approach deeper lesions. 
FNA was used in 1930 for the first time in musculoskeletal tumors by Martin and Ellis and immediately 
with emphasis on its great potential.4 However, its use is far from consensual in the approach of 
mesenchymal tumors. Several factors are on the basis of the existing skepticism such as the small volume 
of sample collected, the fact that it only characterizes the sample cytologically, the overlapping of the 
cytomorphology of various tumors and the large variability of results published in studies over the years.5 
However, given that it is a less invasive procedure, performed on an outpatient basis without general 
anesthesia or hospitalization, as well as having a much lower cost, FNA is an attractive technique when 
compared to more invasive options. The FNA has also the advantage of enabling the aspiration of 
different parts of a same tumor, which is particularly important in large and heterogeneous neoplasms. 
 
Objectives 
 
The aim of this study is to evaluate the diagnostic capacity of fine needle biopsy in musculoskeletal 
lesions, and determine to what extent this method enables the initiation of treatment, clarifying its role 
in the approach of these pathologies. 
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Materials and Methods 
 
Subjects: 
 
After approval of the ethics committee of this institution, retrospective data pertaining to patients of the 
Orthopedics Department of Hospital Santo António - Centro Hospitalar do Port, from 2011 to 2012, was 
collected. This retrospective study from a single center examined the patients that underwent FNA and 
CNB in the same diagnostic procedure. This was followed by data collection, which was achieved by 
reviewing written and electronic patient files. 
Information concerning age, gender, location and type of biopsy performed, imaging method and 
procedure used for FNA, and CNB reports was collected 
88 patients were included, with an average age of 50.2 (range 12-86), 49 (55.7%) males and 39 (44.3%) 
females. 63 underwent bone biopsies and 25 soft tissue biopsies, with variable location: vertebral 
column (n = 20), limbs (n = 51), and pelvis (n = 17). (Table 1)  Imaging control was performed by CT scan 
(n = 54), ultrasonography (n = 18) and radioscopy (n = 16).  (Fig.1) 
 
Table 1 – Clinical characteristics of soft tissue and Bone  
  lesions diagnosed by FNA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Characteristics n % 
Total cases 88 
 
   
Average age(range) 50,2 (12-86) 
 
Male 49 55,7% 
Female 39 44,3% 
   
Type 
  
Bone 63 71,6% 
Soft tissue 25 28,4% 
   
Location 
  
Limbs 51 58,0% 
Spinal column 20 22,7% 
Pelvis 17 19,3% 
   
Image guidance 
  
CT 54 61,4% 
Ultrasound 18 20,5% 
X-ray 16 18,1% 
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Biopsy Procedure 
 
All bone biopsies were performed by the same orthopedic surgeon and the soft tissue biopsies by the 
same radiologist. Before each biopsy, the most suitable route was chosen in order to avoid 
neurovascular structures and important organs, and taking into account the possible "en bloc" excision 
of the tumor. 
After the selection of the area, the path was anesthetized with 3-5 ml of 2% Lidocaine. In the bone 
biopsies, we started with the CNB, using a 8-gauge Zamar catchsystem® needle and after the collection 
of two or three samples, citoaspiration (FNA) with a 22- gauge needle was performed. In the soft tissue 
the procedure was similar, using as a trucut a 14- gauge Bard Magnum® trucut.   
The FNA samples were properly handled and stored, allowing further cytological, histological and 
immunohistochemical studies. 
All samples of either FNA or CNB were analyzed by the same pathologist. In all procedures there were no 
complications. 
 
Statistical analysis 
 
Considering the significant sample available, a descriptive analysis of the information obtained and a 
statistical study of the data using SPSS ® were made. 
The diagnostic performance of FNA was determined by calculating the diagnostic yield (number of 
biopsies with a diagnosis divided by the total number of biopsies) and overall diagnostic accuracy 
(number of biopsies with a diagnosis confirmed by CNB divided by the number of biopsies with a 
Fig.1 –  A - Biopsy of a supra acetabular giant cell tumor guided by CT-scan | B - Biopsy of a thigh 
fibromixossarcoma guided by ultrasonography | C - Biopsy of a metastasis from an adenocarcinoma of the lung 
in the humerus guided by radioscopy 
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diagnosis). For this purpose, we compared the results of this technique with those obtained by the CNB, 
which were considered the control procedure. The samples were classified as either inconclusive or 
conclusive. Within the latter group, the samples were classified as accurate diagnostic or only as allowing 
for distinction between benign and malignant lesions. Some procedures were performed to exclude 
tumor pathology, especially in patients with a previous history of cancer and clinical and imaging signs 
suspected of metastasis. In these cases, if the biopsy is able to exclude tumor pathology, we considered 
the result as "accurate". We also calculated the parameters mentioned above, for evaluating the 
diagnostic capacity in specific subgroups: metastasis, hemolymphatic system tumors, malignant or 
benign primary tumor, infection/inflammatory disease and the exclusion of tumor pathology. 
Later, under the supervision of a specialist in the area, the diagnoses were validated for their therapeutic 
usefulness and the potential for an early treatment. 
 
Results 
Of the 88 patients studied, In 72 patients (81.8%) a diagnosis with fine-needle biopsy was obtained. Of 
these, 63 (71.6%) had an accurate diagnosis, and the remaining 9 (10.2%) the only possible conclusion 
regarded whether the lesion was malignant (n = 2) or benign (n = 7). In 58 (65.9%) the diagnosis was in 
agreement with trucut biopsy, and in 5 (5.7%) the result was incorrect. The fine needle biopsy was 
inconclusive in 16 (18.2%) cases. 
The different diagnoses were divided into subgroups - table2, where it is possible to analyze the 
frequency and relative percentages of each one. 
 
Table 2 – Lesions diagnosed by FNA 
 
 
 
 
 
 
 
 
 
 
 
 
Type of lesion     
     Primary benign tumor 27 30,7% 
     Primary malignant tumor 23 26,1% 
      hemolymphatic neoplasia 10 11,3% 
     Metastatic tumor 16 18,2% 
    Infection/ Inflammatory pathology 7 8,0% 
    Exclusion of pathology 5 5,7% 
Total 88 100% 
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In table 3, it is displayed the distribution of the results of FNAs. It was found that the overall diagnostic 
yield was 81.8 ± 8% (from 73.8 to 89.8%) to a CI of 95%.  
Regarding the overall diagnostic accuracy, since only 5 cases were diagnosed differently, the result was 
92 ± 6.7% (from 85.3 to 98.7%) for CI of 95%.  
 
Table 3 - Diagnostic yield and accuracy according to kind of lesion 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In the same table, the results by subgroup are presented, which highlights the high yield values and 
diagnostic accuracy in the exclusion of tumor pathology (100% for both parameters), metastatic tumor 
(100% in both), hemolymphatic system tumors (80% and 88.9%, respectively) and primary malignant 
tumor (69.6% and 100% respectively).  
The yield and accuracy values obtained in benign tumoral pathology were 40.7% and 84.6%, respectively, 
while in the infection/inflammatory disease these parameters were 28.6% and 50%.  
 
 
 
Type of lesion Diagnostic Yield                 Diagnostic  Accuracy 
     Primary benign tumor 40,7 % (11/27) 84,6% (11/13) 
     Primary malignant tumor 69,6 % (16/23) 100% (16/16) 
     hemolymphatic neoplasia 80,0 % (8/10) 88,9% (8/9) 
     Metastatic tumor 100 % (16/16) 100% (16/16) 
     Infection/Inflammatory pathology 28,6 % (2/7) 50,0% (2/4) 
    Exclusion of tumor pathology 100 % (5/5) 100% (5/5) 
Total 81,8% (72/88) 92% (58/63) 
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In table 4, the 16 cases in which the FNA was inconclusive are displayed. 
 
Table 4 – Inconclusive results in the study 
 
Type of lesion n 
     Primary benign tumor 9 
     Primary malignant tumor 3 
     Infection/Inflammatory pathology 3 
     Hemolymphatic system Tumor 1 
     Metastasis  0 
     Exclusion of tumor pathology 0 
Total 16 
 
About the possibility of initiating treatment- Table 5, the overall value was 90.3 ± 3.5% for a 95% CI, with 
values among subgroups to be lower in inflammatory pathology (75%), then primary malignant tumor 
(80%), hemolymphatic system tumors (88.9%), benign tumor (94.4%), and it presents values of 100% in 
excluding tumoral pathology and in the diagnosis of metastasis. 
 
Table 5 – Possibility to start the treatment according to lesion 
Type of lesion Initial therapy 
     Primary benign tumor 94,4% (17/18) 
     Primary malignant tumor 80,0% (16/20) 
     Hemolymphatic system Tumor 88,9% (8/9) 
     Metastatic tumor 100% (16/16) 
    Infection/ Inflammatory 75% (3/4) 
    Exclusion of pathology 100% (5/5) 
Total 90,3% (65/72) 
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Discussion 
 
The first challenge that the FNA faces is obtaining an appropriate sample - checking whether the sample 
is sufficient in quantity and representative enough to allow the diagnosis. This point is measured by yield, 
and values can vary between 3 and 31% of inadequate samples. 5-6 
There are several reasons that help to explain the wide variation of rates, including the type of lesion 
studied and the accomplishment of preliminary evaluation. The preliminary evaluation comes from the 
observation of the sample by the pathologist during the procedure, allowing its repetition if necessary, 
with substantially improved results when compared to studies where this evaluation is not performed.6-7 
 In our study, the quantity and quality of the sample was determined by the executant alone, without the 
presence of the pathologist.  
Despite the high yield value obtained (81,8%), this parameter was lower than expected in the infection/ 
inflammatory and primary benign pathology subgroups. We attribute this discrepancy to the cellular 
nonspecificity of these lesions, which can guide us to be more selective in the use of FNA. 
The accuracy of a diagnostic technique is the most important parameter in its assessment, seeing as 
obtaining exact result is its main objective. In different studies, the diagnostic accuracy of FNA varies 
between 75% and 98%, where the lowest values are obtained in smaller samples.8-10 If it were only 
considered studies with high samples (n> 300) this value would be greater than 95%.5,7,11,12,13 Thus, the 
importance that specialized centers have in the evaluation and follow-up of these patients is 
understandable, because they can get better results, probably due to greater experience and familiarity 
of health professionals with these tumors. 
In our study the accuracy was equivalent to that found in other reviews, showing the reliability ( >90%) in 
the diagnosis of sarcoma, metastasis, excluding tumor pathology and hemolymphatic system tumor. The 
lower value obtained in infectious/ inflammatory can be interpreted due to the reduced sample 
available, whilst in primary benign tumors, the majority of not accurate diagnosis were in soft tissue 
lesions, possibly pointing to operator bias or to the more friability of the samples what leads to more 
difficulties during the gathering. Would be relevant in a future study with a larger number of cases, 
evaluate the diagnostic performance of fine needle biopsy comparing soft tissue and bone lesions.  
In addition, in many cases of musculoskeletal tumors, the specific diagnosis has a minor role at the start 
of treatment. The histological grade, staging and anatomical location are the most important factors for 
therapeutic decisions, and it may even be said that the existing protocols are less based on the 
histological subtype. Some authors go further, referring to the minor importance of histological subtype 
and highlighting the relevance of the distinction between sarcoma and metastasis, since the treatment 
of most sarcomas in adults is primarily based on its size, location and proximity to vital structures.14 
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The assessment of the patient, integrating imaging information, clinical history and results of FNA, 
permitted initiation of treatment in 90.3%. The values by subgroup were consistently higher especially in 
cases of metastatic disease, hemolymphatic system tumor and in the exclusion of tumoral pathology, 
with the rates of therapeutic orientation being close to 100%, providing economic benefits and less 
morbidity outcomes for the patient.  
Kilpatrick et al. 15 considered FNA sufficient to initiate treatment in 83% of soft tissue tumors and in 87% 
of bone tumors. In a study conducted in 2010, definitive treatment could be initiated, based solely on 
FNA in 81.3% of benign tumors in 78% of malignant and 43% of the indeterminate. 13 
All cytological results should always be interpreted integrating the clinical and imaging context, which 
influence the diagnosis regardless of the diagnostic modality chosen. The value of FNA also depends on 
the operator technique 16 and on the experience of the pathologist.17 
In conclusion, FNA is not intended to be the only technique used in all these lesions. Rather, it should be 
an integral part of the diagnostic plan, perhaps it should be done in first place and, when inconclusive 
perform a more invasive approach. The FNA is a technique with a high potential and is assumed as an 
alternative to trucut biopsy and surgical biopsy and which may prove to have an important role in the 
approach of patients with tumors of soft tissue and bone, even being complemented with other 
techniques. In the cases of metastasis or tumoral recurrence, it is the technique of choice for a first 
analysis, being in most cases the only needed to guide the treatment.18-19  
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